Scholarlink

<p>Breast cancer is the second most common cancer globally and the leading cause of cancer-related deaths in women. Current treatments, such as chemotherapy and surgery, often have side effects and can lead to drug resistance. Developing new treatments that specifically target cancer cells while minimizing side effects is essential. Combining traditional cancer treatments with photodynamic therapy (PDT) is a promising approach. This study evaluated the effectiveness of femtosecond laser-driven PDT using Doxorubicin (DOX) and tetrakis (1-methylpyridinium-4-yl) porphyrin (TMPyP), both individually and in combination, on MDA-MB-231 and T47D breast cancer cells. TMPyP-PDT and DOX monotherapy both exhibited dose-dependent cytotoxicity. However, combination therapy was more effective at lower DOX concentrations, potentially reducing side effects. This combination also increased reactive oxygen species (ROS) levels, inhibited angiogenesis by reducing TGF-β and VEGFA expression, and induced apoptosis by decreasing BCL-2 and increasing BAX levels compared to individual treatments. These findings suggest that combining TMPyP-mediated PDT with Doxorubicin could effectively inhibit breast cancer cell growth.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Water-soluble porphyrin-mediated enhanced photodynamic and chemotherapy employing doxorubicin for breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月23日

查看全文
  • Aya Mokhtar,
  • Tarek Mohamed,
  • Ahmed O. Eigza,
  • Mohamed E. El-Khouly

摘要

Breast cancer is the second most common cancer globally and the leading cause of cancer-related deaths in women. Current treatments, such as chemotherapy and surgery, often have side effects and can lead to drug resistance. Developing new treatments that specifically target cancer cells while minimizing side effects is essential. Combining traditional cancer treatments with photodynamic therapy (PDT) is a promising approach. This study evaluated the effectiveness of femtosecond laser-driven PDT using Doxorubicin (DOX) and tetrakis (1-methylpyridinium-4-yl) porphyrin (TMPyP), both individually and in combination, on MDA-MB-231 and T47D breast cancer cells. TMPyP-PDT and DOX monotherapy both exhibited dose-dependent cytotoxicity. However, combination therapy was more effective at lower DOX concentrations, potentially reducing side effects. This combination also increased reactive oxygen species (ROS) levels, inhibited angiogenesis by reducing TGF-β and VEGFA expression, and induced apoptosis by decreasing BCL-2 and increasing BAX levels compared to individual treatments. These findings suggest that combining TMPyP-mediated PDT with Doxorubicin could effectively inhibit breast cancer cell growth.